抗原自我呈现的树突体吞纳米疫苗增强抗原和STING激动剂的配送用于癌症免疫疗法
Jiaxuan Xia1, Xing Chen1, Meichen Dong1
1Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai Institute of Infectious Disease and Biosecurity, Shanghai, 201203, China.
这项研究开发了一种新型的癌症疫苗,使用纳米粒子和树突体,以改善抗原和辅助剂的传递到免疫细胞. 这种策略通过促进细胞毒性T淋巴细胞反应来增强抗瘤免疫力.
科学领域:
- 免疫学 免疫学 免疫学
- 纳米技术纳米技术
- 癌症研究 癌症研究
背景情况:
- 癌症疫苗的目的是刺激瘤特异性细胞毒性T淋巴细胞 (CTL) 反应.
- 对抗原和辅助剂向树突细胞 (DCs) 的有效细胞质传递对抗瘤免疫至关重要.
- 目前的方法面临的挑战是内分体降解和离子纳米载体的非目标效应.
研究的目的:
- 开发一种新的纳米疫苗策略,以增强抗原和辅助剂的细胞质共递.
- 改进淋巴结 (LN) 定位和DC定位,同时最大限度地减少目标之外的积累.
- 通过改善DC激活和CTL诱导来增强抗瘤免疫反应.
主要方法:
- 开发了与抗原和循环-二-GMP (cdGMP) 共同加载的阴离子聚胺 (NP) 纳米粒子 (cG,OVA).
- 这些纳米颗粒被封装在DCs衍生型树突体 (ODs) 中,形成ODs/NP(cG,OVA).
- 评估了向,细胞吸收,细胞质递送,DC成熟和CTL反应.
主要成果:
- 与NP (cG,OVA) 相比,ODs/NP (cG,OVA) 显示肝脏积累减少,并增强了针对LNs和DCs的向.
- 该纳米疫苗促进了抗原和cdGMP在DC中的细胞共递,促进了抗原呈现和成熟.
- ODs/NP ((cG,OVA) 有效诱导抗原特异性CTL激活,增殖和分化.
结论:
- 开发的树突体封装纳米疫苗 (ODs/NP(cG,OVA)) 是癌症免疫疗法的有效策略.
- 这种方法克服了内分体降解和非标效应的局限性,提高了疫苗的疗效.
- 该策略通过增强的CTL反应,提供强大的免疫保护,防止瘤入侵.
更多相关视频
10:35Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
Published on: February 5, 2021
07:33Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022
相关概念视频
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
Tumor Immunotherapy
Antigen Presenting Cells
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
Vaccinations
Cross-reactivity
